This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.
The primary objective of this 3-arm clinical trial is to compare progression-free survival (PFS) of LNS8801 + pembrolizumab arm vs Physicians’ Choice (PC) treatment using RECIST 1.1.
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability an...
This phase 3 study will evaluate the superiority of the fixed dose combination (FDC) of fianlimab + cemiplimab versus the FDC of relatlimab + nivolumab (referred to as Opdualag™) in participants with unresectable locally advanced or metastatic melanoma.
A study to investigate the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen plus pembrolizumab infusions compared with pembrolizumab infusions alone in participants with untreated, unresectable or metastatic melanoma
The purpose of this study is to obtain long-term data for disease response, overall survival (OS), and progression-free survival (PFS), and the subsequent use of anti-cancer treatments in patients with melanoma, who had previously been treated with fianlimab and cemiplimab.
To evaluate the efficacy of IMA203 compared with control (investigator's choice)
We want to find out if using RP2 with nivolumab works better than using ipilimumab with nivolumab to help adults with eye cancer that has spread and cannot be removed by surgery live longer.
This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and ...
To compare the objective response rate (ORR) between subjects treated with intralesional administration of IFx-Hu2.0, as an adjunctive therapy, followed by pembrolizumab, and subjects treated by placebo followed by pembrolizumab using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
This is a first-in-human study to learn more about the investigational drug EBC-129. This study will assess the safety and tolerability of EBC-129 when given alone and in combination with pembrolizumab in patients with advanced solid tumors.
This is a first-in-human study. The main goal of this study is to assess the safety and tolerability of mRNA-4359 given alone and in combination with pembrolizumab.
This is a first-in-human study. The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines (called binimetinib) in people with solid tumors.
This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic ce...
The overall objective of this study is to ultimately develop an improved standard of cancer care by facilitating new clinical trials, new technology, new informatics solutions and "personalized medicine".